Zacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) to Announce -$0.14 EPS

Wall Street analysts expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to report earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.15). Pieris Pharmaceuticals reported earnings of ($0.16) per share in the same quarter last year, which indicates a positive year over year growth rate of 12.5%. The business is expected to report its next quarterly earnings results on Wednesday, March 28th.

On average, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.73) to ($0.70). For the next fiscal year, analysts forecast that the company will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.74) to ($0.51). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The company had revenue of $3.93 million for the quarter, compared to analysts’ expectations of $1.52 million. The firm’s quarterly revenue was up 400.3% compared to the same quarter last year.

Several research firms have issued reports on PIRS. William Blair began coverage on shares of Pieris Pharmaceuticals in a research note on Wednesday. They set an “outperform” rating on the stock. HC Wainwright raised their price target on shares of Pieris Pharmaceuticals from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday. BidaskClub raised shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $10.00.

Pieris Pharmaceuticals (NASDAQ:PIRS) traded up $0.02 during trading on Monday, hitting $7.37. 220,830 shares of the company’s stock traded hands, compared to its average volume of 475,869. Pieris Pharmaceuticals has a one year low of $1.66 and a one year high of $7.90. The firm has a market cap of $330.13, a PE ratio of -10.10 and a beta of -76.25.

In other news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total transaction of $12,565,707.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.05% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. Creative Planning lifted its holdings in shares of Pieris Pharmaceuticals by 18.2% during the 4th quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after acquiring an additional 12,000 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Pieris Pharmaceuticals by 14.0% during the 4th quarter. Acadian Asset Management LLC now owns 116,154 shares of the biotechnology company’s stock worth $877,000 after acquiring an additional 14,263 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Pieris Pharmaceuticals by 107.5% during the 3rd quarter. New York State Common Retirement Fund now owns 33,000 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 17,100 shares during the period. Wells Fargo & Company MN purchased a new position in shares of Pieris Pharmaceuticals during the 3rd quarter worth about $105,000. Finally, Bank of Montreal Can purchased a new position in shares of Pieris Pharmaceuticals during the 4th quarter worth about $144,000. Institutional investors and hedge funds own 50.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) to Announce -$0.14 EPS” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/19/zacks-brokerages-expect-pieris-pharmaceuticals-inc-pirs-to-announce-0-14-eps.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply